Clario’s Otis Johnson, Ph.D., honored as impact leader finalist by Informa’s Biotech Week Boston Awards
Chief Diversity, Inclusion, and Sustainability Officer recognized for their environmentally-conscious efforts towards sustainability and good governance
PHILADELPHIA, PA – October 6, 2022 –, Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, announced that Otis Johnson, Ph.D., Chief Diversity, Inclusion, and Sustainability Officer, has been recognized as a finalist for the Impact Leader Award at Informa’s Biotech Week Boston (BWB) Awards. The BWB Impact Leader award is in recognition of environmentally conscious efforts toward sustainability and good governance.
“We do not believe enough is being done to measure and reduce the carbon footprint of the clinical trial industry, so we have stepped up to measure and reduce our environmental impact. We are firm in the knowledge that healthy patients can only thrive on a healthy planet.“
“The BWB Impact Leader award recognition comes because of strong contributions from all Clario’s people, from our interns through to the CEO. We needed accurate data from suppliers and thousands of employees to understand the true impact of our global operations. Collaboration, transparency and accuracy are key enablers for Clario,” said Dr. Johnson.
Within a year, highly engaged employees made it possible for the organization to:
- Robustly measure its carbon footprint and identify targeted areas for emission reductions
- Reduce its global office footprint
- Switch its largest facility to 100% green energy
- Redesign products and packaging for efficiency and reduced environmental impact
- Adjust its service delivery models and logistics
- Create new value out of retired devices and technology through donations
“Through our own operations, we have the power to reduce health disparities and do so while positively impacting the planet. Clario’s go-forward strategy on our journey to net-zero is data driven and grounded in science. We aspire to be good corporate citizens to both people and planet”, said Dr. Johnson.
Dr. Johnson was recently named to the prestigious Pharmavoice100 list of most inspiring life-science industry leaders, and named a Mogul Top 100 Diversity, Equity and Inclusion (DEI) leader for his significant contributions to increasing the diversity of clinical trial participants and throughout the clinical trial workforce. He applied the same winning DEI approach to his environmental strategy, going after the data and actionable business insights, to form a multiyear strategy with specific and measurable environmental goals.
The BWB Awards recognize individuals and organizations who have made positive and innovative contributions to the life sciences industry. Finalists were recognized and winners were announced at a ceremony in Boston, MA on September 27.
Learn more about Clario’s environmental, social, and governance (ESG) work.
About Clario
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.
For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.
For more information, go to Clario.com or follow us on LinkedIn.
Media Contact:
David Malley
Director of Brand, Content Strategy, and Communications
[email protected]